Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

Start Date01 Dec 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

NCT06954129

/ Not yet recruitingPhase 4IIT

Markers of Nephrotoxicity During Treatment With Antibiotic Combinations: A Pragmatic Clinical Trial

Hospitalized patients with suspected or confirmed infection are commonly treated with vancomycin (VN) in combination with either piperacillin-tazobactam (PT) or cefepime (CP). Although these regimens have similar effectiveness, recent observational evidence suggests they may differ in terms of the risk for acute kidney injury (AKI). Interpretation of existing evidence is complicated by the limitations of creatinine, the standard biomarker used to monitor kidney function, which has poor sensitivity and specificity for drug induced AKI. To address this important knowledge gap, the investigators propose to conduct a pragmatic, open-label, non-inferiority trial that will examine the comparative risk of AKI between these standard-of-care antibiotic combinations using sensitive and specific markers of drug-induced AKI. We hypothesize that the regimen of VN in combination with PT (VN+PT) is noninferior to the regimen of VN in combination with CP (VN+CP) in terms of AKI risk.

Start Date01 Oct 2025

Sponsor / Collaborator

University of Pennsylvania

NCT06406114

/ RecruitingPhase 2IIT

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

Start Date05 May 2025

Sponsor / Collaborator

The General Hospital Corp.

[+1]

100 Clinical Results associated with Cefepime hydrochloride

100 Translational Medicine associated with Cefepime hydrochloride

100 Patents (Medical) associated with Cefepime hydrochloride

8,564

Literatures (Medical) associated with Cefepime hydrochloride

01 Jun 2026·One Health

Prevalence and risk factors of antimicrobial resistance in Staphylococcus spp. and Escherichia coli in fruit bats at high-risk human-wildlife interfaces in Bangladesh

Article

Author: Flora, Meerjady Sabrina ; Islam, Ariful ; Rumi, Md Aftabuddin ; Sagor, Md Shahjalal ; Samad, Mohammed Abdus ; Islam, Monjurul ; Hossain, Muhammad Sazzad ; Islam, Shariful ; Epstein, Jonathan H ; Uddin, Md Helal ; Rahman, Md Kaisar ; Dutta, Pronesh ; Forwood, Jade K ; Chowdhury, Sharmin

Antimicrobial resistant (AMR) bacteria are frequently detected in wildlife and are often considered an indicator of anthropogenic pathogen exposure to wildlife. However, the role of bats in AMR dissemination remains poorly understood. We conducted a cross-sectional study to investigate the prevalence and risk factors associated with AMR patterns in Staphylococcus spp. and Escherichia coli isolated from frugivorous bats in Bangladesh. We collected 369 noninvasive fecal samples from Pteropus medius and Rousettus leschenaultii individual bats. Bacterial isolation was performed using selective media, biochemical tests and performed polymerase chain reaction (PCR) for confirmation of Staphylococcus spp. and E. coli. Antimicrobial susceptibility testing for antimicrobials was conducted using the Kirby-Bauer disc diffusion technique. The prevalence of E. coli and Staphylococcus spp. was 29.8 % and 28.5 % respectively. Overall, 28.2 % of E. coli and 26.3 % of Staphylococcus spp. exhibited resistance to at least one antimicrobial. Logistic regression analysis revealed that resistant Staphylococcus spp. colonisation was significantly higher in rural areas (OR = 2.6) and in R. leschenaulti i species (OR = 2.6), while resistant E. coli was higher in urban areas (OR = 2.0) and in P. medius bat (OR = 1.7). Staphylococcus spp. showed the highest resistance to ampicillin (56 %), followed by clindamycin (23 %). On the other hand, E. coli showed the highest resistance against cefepime (16 %) followed by ampicillin (13 %). While the source of AMR bacteria in bats remains unclear, bat drinking habits on the contaminated water bodies with people and domestic animals might be source of resistant bacteria to bats. Future One Health research is recommended to understand the ecology of AMR and role of bats in the transmission of resistant bacteria across ecosystems.

01 Mar 2026·Indian Journal of Medical Microbiology

“In vitro evaluation of sulbactam combination therapies for Acinetobacter baumannii”

Article

Author: Wig, Naveet ; Sood, Seema ; Vaitheeswaran, Karthick Kumar ; Kapil, Arti ; Soneja, Manish ; Pandey, Shivam ; Ray, Animesh

BACKGROUND AND OBJECTIVES:

Acinetobacter baumannii, a leading cause of hospital-acquired infections in critically ill patients, is increasingly resistant to carbapenems, leading WHO to designate carbapenem-resistant Acinetobacter baumannii (CRAB) as a critical priority pathogen. While the 2024 IDSA guidelines recommend sulbactam-based regimens as the cornerstone of therapy, high-dose sulbactam is effective only against isolates with MICs up to 16-32 μg/mL. This study aimed to describe the sulbactam MIC distribution and to evaluate MIC reduction and synergy when combined with β-lactam antibiotics against CRAB.

METHODS:

CRAB isolates from respiratory samples of ventilator-associated pneumonia patients were tested using E-tests to determine MICs of individual antibiotics. Combinations of sulbactam with ceftriaxone, cefepime, and meropenem were assessed using the E-test cross method. Synergy was evaluated by the FIC index: synergy (≤0.5), additive (>0.5-1), indifference (>1-<4), and antagonism (≥4).

RESULTS:

Thirty-five non-duplicate CRAB isolates were tested. All isolates were resistant to ceftriaxone, cefepime, and meropenem when tested individually, with MICs exceeding E-test detection limits. Hence, although sulbactam combinations significantly reduced MICs, the resulting values often remained above CLSI-defined susceptibility breakpoints. Notably, sulbactam alone showed an MIC₅₀ of 12 μg/mL and an MIC₉₀ of 24 μg/mL. In combination, sulbactam MIC₅₀/MIC₉₀ values were reduced to 8/24 μg/mL with ceftriaxone, 6/16 μg/mL with cefepime, and 8/24 μg/mL with meropenem. Sulbactam-cefepime showed the highest synergy (11.43 %) and additive effects (34.29 %), followed by sulbactam-ceftriaxone (2.86 % synergy; 31.43 % additive). Sulbactam-meropenem showed no synergy but 31.43 % additive effects. No antagonism was observed with any combination.

CONCLUSION:

Combining sulbactam with β-lactams, particularly cefepime, significantly reduced sulbactam MICs. However, the β-lactam MICs themselves remained largely within not-susceptible ranges, highlighting that the observed benefit was confined primarily to sulbactam rather than the companion β-lactams. These findings supported further clinical studies of high-dose sulbactam-β-lactam combinations to optimize the pharmacodynamic efficacy of sulbactam against CRAB strains with elevated MICs.

01 Feb 2026·JOURNAL OF CRITICAL CARE

Authors' response: “Observational study of cefepime therapeutic drug monitoring in continuous venovenous hemodialysis”

Letter

Author: Hanretty, Alexandra ; Wageh, John ; Delic, Justin ; Kim, Soyoung ; Pasciolla, Stacy ; Igneri, Lauren A ; Kludjian, Geena ; Chau, Terence

News (Medical) associated with Cefepime hydrochloride

15 Dec 2025

·www.everestmedicines.com

Everest Medicines Announces 2030 Strategy and Increase in Shareholdings by Directors and Substantial Shareholder

Shanghai, China – December 15, 2025 – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the launch of its 2030 Strategy, outlining a comprehensive five-year roadmap to drive sustainable growth. Under this strategy, the Company aims to further deepen its product pipeline, maximize the value of its commercial platform, and advance the globalization of its research and development (“R&D”) and commercialization capabilities. In parallel, the Company also announced that certain Directors and a substantial shareholder have increased their shareholdings in the Company. On December 12, 2025, Mr. Wei Fu, Non-executive Director, Honorary Chairman of the Board and a substantial shareholder of the Company; Mr. Yifang Wu, Executive Director and Chairman of the Board; Mr. Rogers Yongqing Luo, Executive Director and Chief Executive Officer; and Mr. Ian Ying Woo, Executive Director, President and Chief Financial Officer, collectively acquired 846,659 ordinary shares of the Company through open-market transactions, for a total consideration exceeding HK$38 million, representing an average price of approximately HK$45.01 per Share. In addition, the Company has been informed that CBC Group, a substantial shareholder of the Company, has further undertaken that it plans to increase its shareholding by not more than 1% in aggregate in the following three to six months, subject to the market conditions and compliance with applicable laws and regulatory requirements. The Board believes that a voluntary share purchase through on-market acquisitions of Shares by the Directors and the undertaking given by CBC Group signify strong confidence in the future prospects and long-term development of the Company. 2030 Strategy Overview The Company’s 2030 strategy sets out a dual-engine approach to deliver predictable near-term growth and value creation through commercialization of existing assets, business development partnerships, and in-house R&D milestones, while driving long-term growth and value creation through in-house R&D and discovery, as well as global commercial expansion. Everest Medicines will continue to strengthen its leadership in core therapeutic areas, advance the development and commercialization of innovative therapies, and build a globally competitive biopharmaceutical company with sustainable growth. Everest Medicines focuses on renal, autoimmune, critical care, cardiovascular, and ophthalmic disease area, advancing its pipeline through a combination of in-licensed innovative assets and in-house R&D. By 2030, the Company aims to build a high-value commercial product portfolio while selectively expanding into additional valuable therapeutic areas with blockbuster potential. The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle. By 2030, Everest Medicines targets annual revenue exceeding RMB 15 billion, including approximately RMB 9 billion from its existing pipeline and RMB 6 billion from newly in-licensed assets, while also exploring potential out-licensing opportunities. Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafter. Over the same period, the number of commercial products is expected to exceed 20, including NEFECON®, Velsipity®, XERAVA®, cefepime–taniborbactam, and Lerodalcibep. To support its international growth, Everest Medicines is advancing a global strategy focused on strengthening regulatory and clinical development capabilities, while progressively building commercial infrastructure across Europe, the United States, and emerging markets. By 2030, the Company aims to drive growth through a combination of overseas out-licensing and direct commercialization, accelerating its global expansion. Through this strategy, Everest Medicines aims to strengthen its position in core therapeutic areas and innovative drug R&D, while building a globally competitive biopharmaceutical company with sustainable growth. As a major shareholder of NovaBridge Biosciences, holding approximately 16% of its issued share capital, the Company will collaborate with NovaBridge Biosciences to identify high-quality assets and enhance global R&D and commercialization capabilities through complementary strengths and resources. “The 2030 Strategy reflects Everest Medicines’ clear vision for commercialization, R&D, and global expansion, and reinforces the Company’s ability to deliver sustainable value. Since its founding in 2017, the Company has built a strong foundation through in-licensing innovative assets, completing its IPO, and executing a dual-engine strategy focused on high-potential therapeutic areas and strong commercialization and R&D capabilities,” said Mr. Wei Fu, Honorary Chairman of the Board of Everest Medicines and CEO of CBC Group. “CBC Group will continue to leverage its global resources and ecosystem to support the Company’s growth, spanning pipeline advancement, platform building, and organizational expansion. The recent share purchases by the Directors and CBC Group’s announced intention to increase its shareholding further demonstrate strong confidence in Everest Medicines’ long-term prospects.” “The 2030 Strategy marks a key milestone for Everest Medicines, guiding growth through BD partnerships and in-house R&D to build a larger commercial portfolio and pursue new high-potential blockbuster opportunities. Leveraging its BD capabilities and the CBC ecosystem, the Company plans to add three-to-five late-stage, high-value assets annually, aiming for peak sales within three years of reimbursement, with more than 20 new assets expected to contribute around RMB 6 billion by 2030 and RMB 30 billion by 2035. Our strong balance sheet and cash flow from commercial activities will support the implementation of our strategic initiatives.” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “We will also continue to advance our in-house R&D platforms and, through our collaboration with Hasten, strengthen the late-stage pipeline and market reach.” “Everest has established a scalable commercialization platform integrating medical, access, marketing, and sales capabilities,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “As a chronic disease therapy, NEFECON® generated over RMB 1 billion in sales during the first three quarters of its first full year following commercial launch, validating our commercial effectiveness. Building on this success, we will extend our commercial model and expertise from renal and anti-infective therapies to additional therapeutic areas, while advancing our in vivo mRNA CAR-T and mRNA tumor vaccine platforms, addressing unmet medical needs in China and globally.” About Everest Medicines Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that address critical unmet medical needs for patients in Asian markets. The management team of Everest Medicines has deep expertise and an extensive track record from both leading global pharmaceutical companies and local Chinese pharmaceutical companies in high-quality discovery, clinical development, regulatory affairs, CMC, business development and operations. Everest Medicines has built a portfolio of potentially global first-in-class or best-in-class molecules in the company’s core therapeutic areas of renal, autoimmune, critical care, cardiovascular, and ophthalmic diseases. For more information, please visit its website at www.everestmedicines.com. Forward-Looking Statements This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

VaccineAcquisitionIPO

03 Oct 2025

·pharma.economictimes.indiatimes.com

Wockhardt seeks FDA nod for novel antibiotic Zaynich

New Delhi: Mumbai-based drugmaker Wockhardt is seeking marketing approval for its novel antibacterial agent Zidebactam-Cefepime branded as 'Zaynich' in the US. In a release the company announced the submission of a New Drug Application (NDA) of Zaynich to the US FDA for the treatment of complicated urinary tract infections (cUTI), caused by bacteremia caused by Gram-negative bacteria including multidrug-resistant (MDR). Zaynich, an antibiotic engineered to treat drug-resistant bacterial infections involves two agents, Cefepime and Zidebactam, which disrupts cell wall formation, and binds a key protein (PBP2) in bacteria essential for their survival. Wockhardt has moved the candidate into the approval stage following the successful completion of Phase III trial (ENHANCE 1), conducted across 64 sites where it demonstrated “over 97 per cent clinical efficacy” in treating seriously ill patients with infections caused by carbapenem-resistant Gram-negative pathogens. The novel antibiotic is completely discovered and developed by Wockhardt, has been granted qualified infectious disease product (QIDP) and FTD from the US FDA. According to the drugmaker, in the US and EU, more than 8 million cUTI cases are reported every year and Gram-negative infections have become increasingly difficult to treat due to widespread resistance to multiple classes of antibiotics. However, with its novel mechanism of action, Zaynich has the potential to treat a broad range of infections caused by multi-drug resistant (MDR) and extreme drug resistant (XDR) pathogens, it added. Notably, the submission comes months after the company had announced to exit the US generics segment to sharpen its focus on its innovative portfolio of “antibiotics and insulin.” The company had filed for voluntary liquidation under Chapter 7 of the US Bankruptcy Code for its step down subsidiaries, Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC, and the decision is effective from July 11, 2025. By Online Bureau ,

Phase 3Qualified Infectious Disease ProductNDAPriority Review

14 Aug 2025

·pipelinereview.com

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

ALLSCHWIL, Switzerland I August 14, 2025 I Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive license agreement with Venatorx Pharmaceuticals, Inc., to acquire the global rights to ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for the potential treatment of complicated urinary tract infections (cUTI), including pyelonephritis. Ceftibuten-ledaborbactam etzadroxil is the combination of ceftibuten, an orally bioavailable cephalosporin antibiotic, and ledaborbactam etzadroxil, the orally bioavailable prodrug of the novel beta-lactamase inhibitor ledaborbactam. The combination demonstrates bactericidal activity against Enterobacterales, including multidrug-resistant pathogens, the major cause of cUTI. [1] In the USA, cUTI account for more than 600,000 hospital admissions each year. [2] This underscores the significant clinical burden and need for effective oral treatment options, which may shorten or entirely avoid hospitalization. In preclinical and clinical phase 1 studies, ceftibuten and ledaborbactam etzadroxil were shown to be safe and well tolerated. [3] David Veitch, Chief Executive Officer of Basilea, said: “This agreement allows us to strengthen our late-stage clinical pipeline and supports our strategy of ensuring that we have a continuous stream of potential new product launches in the near-term future, positioning us for sustainable substantial revenue growth. Ceftibuten-ledaborbactam etzadroxil holds strong promise in addressing the critical unmet need for the oral treatment of cUTI caused by multidrug-resistant Gram-negative bacteria and represents a compelling global commercial opportunity. We expect starting a registrational phase 3 program in cUTI in about 18 months.” Under the terms of the agreement, Basilea will make an upfront payment and potential milestone payments in 2025. Following the successful completion of the phase 3 clinical development program and after the grant of regulatory approval and start of commercialization, Venatorx is eligible to receive tiered mid-single-digit royalties and additional potential milestone payments of up to USD 325 million in total, if all agreed commercial milestone events are triggered over the term of the contract. The transaction is expected to result in approximately CHF 15 million of additional research and development expenses in 2025, including the full upfront payment, all potential pre-commercial milestone payments and expected R&D expenses in 2025. Basilea will provide updated financial guidance for the full-year 2025, reflecting this transaction, with the half-year earnings report on August 19, 2025. About beta-lactam/beta-lactamase inhibitor (BL/BLI) combinations Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections by multidrug-resistant bacterial pathogens. About ceftibuten-ledaborbactam etzadroxil Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. [4] Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. About complicated urinary tract infections (cUTI) Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. [1] Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48). About Venatorx Pharmaceuticals, Inc. Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx also developed cefepime-taniborbactam, an intravenous-only antibiotic that successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis. The ceftibuten-ledaborbactam etzadroxil project has been funded in whole or in part with Federal funds from National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201600029C and the Department of Health and Human Services; Office of the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50123C00050. For more information about Venatorx and its anti-infectives portfolio, please visit www.venatorx.com . About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com . References SOURCE: Basilea

Phase 3License out/inDrug ApprovalPhase 1Fast Track

100 Deals associated with Cefepime hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D01157	Cefepime hydrochloride	J01DE01	DB01413

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bronchiectasis	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Cholangitis	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Cholecystitis	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Chronic disease of respiratory system	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Cystitis	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Gonococcal urethritis	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Otitis Media	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Scarlet Fever	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Sinusitis	South Korea	Shinpoong Pharmaceutical Co., Ltd.	31 May 2024
Biliary tract infection	Australia	Strides Pharma Science Ltd.	26 Aug 2010
Bronchitis	Australia	Strides Pharma Science Ltd.	26 Aug 2010
Gynecological infection	Australia	Strides Pharma Science Ltd.	26 Aug 2010
Peritonitis	Australia	Strides Pharma Science Ltd.	26 Aug 2010
Pyelonephritis	Australia	Strides Pharma Science Ltd.	26 Aug 2010
Non-complicated skin and skin structure infection	United States	Baxter Healthcare Corp.	05 Aug 2008
Complicated intra-abdominal infection	China	Bristol-Myers Squibb Srl	23 Jul 2004
Lower Respiratory Tract Infections	China	Bristol-Myers Squibb Srl	23 Jul 2004
Meningitis, Bacterial	China	Bristol-Myers Squibb Srl	23 Jul 2004
Neutropenia	China	Bristol-Myers Squibb Srl	23 Jul 2004
Sepsis	China	Bristol-Myers Squibb Srl	23 Jul 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Urethral Infection	Phase 1	United States	Seachaid Pharmaceuticals, Inc.	30 Jan 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05102162 (CTgov)	Phase 4	Pneumonia	35	Meropenem+Piperacillin/Tazobactam+Cefepime (Continuous Antibiotic Dose Over 24 Hours Arm)	aekmrpfkzf = pieuwcwvqt jiafsafesk (ykzhqawlit, pqpqigaong - qgsoaotuwq) View more	-	12 Dec 2023
				Meropenem+Piperacillin/Tazobactam+Cefepime (Intermittent Antibiotic Dose Over 30 Minutes)	aekmrpfkzf = qmbzvulfqx jiafsafesk (ykzhqawlit, jduddvlyce - qpxctfdytu) View more
NCT02872038 (Pubmed \| Am J Kidney Dis)	Phase 4	Peritoneal dialysis-associated peritonitis	144	IP cefepime monotherapy	nmicylknxp(gyxhiqqgwv) = rcwtspwkee qbxhgikjvj (xinrcemzlj ) View more	-	01 Nov 2019
				IP combination of cefazolin and ceftazidime	nmicylknxp(gyxhiqqgwv) = ygiyhabkqi qbxhgikjvj (xinrcemzlj ) View more
ERS2019	Not Applicable	Pneumonia	43	Cefepime with Ciprofloxacin	dabszkdtmb(fspjonnxop) = ddruobakfy krqeeacwgf (sqsormmkmm ) View more	-	28 Sep 2019
				Piperacillin/tazobactam with Ciprofloxacin	dabszkdtmb(fspjonnxop) = juymnaaagn krqeeacwgf (sqsormmkmm ) View more
NCT03680612 (CACTUS, PipelineReview) Manual	Phase 2	Complicated lower urinary tract infection	45	AAI101+cefepime	dyyqkokbkd(qxgyudmzei) = lvceeyzasz ntshwlppxe (kfwzxloatv ) View more	Positive	26 Mar 2018
				cefepime	dyyqkokbkd(qxgyudmzei) = zwssfjramn ntshwlppxe (kfwzxloatv ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis